Veraxa Biotech AG Ordinary Shares (VRXA)
Stock · NASDAQ · Health Care
$1.11as of 10/16/2026
Price chart
Active signals
VRXA Signal Track Record
How signals performed across all stocks →What VRXA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 9 | +0.4% | 67% | June 8, 2026 |
| Volume Spike | 7 | +0.3% | 57% | October 6, 2026 |
| Bollinger Band Breakdown | 5 | -0.7% | 40% | October 2, 2026 |
| Any 20-session window (baseline) | +0.3% | 63% |
Computed by MarketWall from daily closing prices since July 18, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VRXA
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical deve…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Fundamentals
- 1-day range
- $1.12$1.35
- Market cap
- $263.02M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.58
- Dividend yield
- —
- Beta
- 0.48
- Avg. volume
- 282.1K
Veraxa Biotech AG Ordinary Shares Competitors
Chosen by industry and closest market cap.
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- RNACCartesian Therapeutics Inc. Common Stock$6.27▼ 4.71%Market cap $257.38MP/E —$5.6$11
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| RNAC Cartesian Therapeutics Inc. Common Stock | $257.38M | — | $6.27 | ▼ 4.71% | $5.6$11 |
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half ProgressYahoo · 9/24/2026
- VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next PhaseYahoo · 9/22/2026
- VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology PipelineYahoo · 9/18/2026
- VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer TherapyYahoo · 9/16/2026
Insider Activity
Insider Actions →- Hosseinion Warren · September 10, 2026 · Buy6.0K @ $1.67
- Baumann Oliver Rolf · August 27, 2026 · Buy50.0K @ $1.5
- Antz Christoph Rudiger · August 27, 2026 · Buy5.0K @ $1.53
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Veraxa Biotech Advances Oncology Pipeline with Xlife First‑Half Progress
Xlife Sciences released first‑half results showing progress on Veraxa’s BiTAC platform, expanding the company’s oncology pipeline. The update signals that Veraxa’s public‑market story is moving into its next development phase. These developments add depth to the company’s pipeline, which could support future product launches.
Veraxa Biotech Advances Oncology Pipeline with Xlife First‑Half Progress. Xlife Sciences released first‑half results showing progress on Veraxa’s BiTAC platform, expanding the company’s oncology pipeline. The update signals that Veraxa’s public‑market story is moving into its next development phase. These developments add depth to the company’s pipeline, which could support future product launches.